Lipocine Inc. (NASDAQ:LPCN)’s share price fell 4.1% on Monday . The stock traded as low as $3.54 and last traded at $3.54, with a volume of 73,428 shares trading hands. The stock had previously closed at $3.69.

Separately, Canaccord Genuity reiterated a “buy” rating and issued a $6.00 price target (down from $15.00) on shares of Lipocine in a research report on Saturday, July 2nd.

The stock’s 50 day moving average is $4.57 and its 200-day moving average is $8.44. The firm’s market capitalization is $64.91 million.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.05. On average, equities research analysts expect that Lipocine Inc. will post ($1.33) EPS for the current fiscal year.

An institutional investor recently raised its position in Lipocine stock. Dimensional Fund Advisors LP increased its stake in Lipocine Inc. (NASDAQ:LPCN) by 73.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 271,272 shares of the specialty pharmaceutical company’s stock after buying an additional 114,448 shares during the period. Dimensional Fund Advisors LP owned approximately 1.49% of Lipocine worth $3,508,000 at the end of the most recent quarter.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.